- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07644000
Effect of Pre-exercise Inhalation of Molecular Hydrogen on Metabolic Response During Graded Exercise in Healthy Women
Effect of Repeated Pre-exercise Inhalation of Molecular Hydrogen on Metabolic Response During Graded Exercise in Healthy Women: A Randomized, Double-blind, Placebo-controlled Crossover Trial
The goal of this clinical trial is to evaluate if molecular hydrogen can reduce the metabolic response during graded exercise in healthy women aged 18-30 years. The main questions it aims to answer are:
- Does molecular hydrogen reduce the respiratory exchange ratio?
- Does molecular hydrogen reduce oxygen uptake?
Researchers will compare molecular hydrogen to a placebo (ambient air containing no molecular hydrogen) to see if molecular hydrogen reduces the metabolic response.
Participants will:
- Inhale molecular hydrogen for 60 minutes each day for 7 days.
- Undergo an exercise testing twice after a two-week washout period.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Tereza Rysava
- Telefoonnummer: +420585636154
- E-mail: tereza.rysava01@upol.cz
Studie Contact Back-up
- Naam: Jakub Krejci, PhD
- E-mail: jakub.krejci@upol.cz
Studie Locaties
-
-
-
Olomouc, Tsjechië, 77111
- Werving
- Palacky University, Faculty of Physical Culture
-
Contact:
- Tereza Rysava
- Telefoonnummer: +420585636154
- E-mail: tereza.rysava01@upol.cz
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Healthy female participants.
- Regular menstrual cycle with exercise testing scheduled outside the menstrual phase.
- Signed informed consent.
Exclusion Criteria:
- Pregnancy or breastfeeding.
- History or presence of cardiovascular disease.
- History or presence of respiratory disease.
- Regular use of medications affecting metabolism.
- Use of dietary supplements affecting metabolism within 14 days prior to intervention.
- Strenuous physical activity within 24 hours prior to exercise testing.
- Any contraindication to exercise testing or study participation determined by a physician.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Fundamentele wetenschap
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Molecular hydrogen
Molecular hydrogen inhalation for 60 minutes daily for 7 days.
|
Gas mixture containing 3.75% molecular hydrogen and ambient air.
Andere namen:
|
|
Placebo-vergelijker: Placebo
Ambient air inhalation for 60 minutes daily for 7 days.
|
Ambient air without molecular hydrogen.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Respiratory exchange ratio
Tijdsspanne: Change after 2 weeks of crossover.
|
Respiratory exchange ratio is measured using an Ergostik analyser (Geratherm Respiratory, Bad Kissinger, Germany) breath by breath during the exercise, and the average is calculated for 6-minute segments for subsequent analysis.
|
Change after 2 weeks of crossover.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Oxygen uptake
Tijdsspanne: Change after 2 weeks of crossover.
|
Oxygen uptake is measured using an Ergostik analyser (Geratherm Respiratory, Bad Kissinger, Germany) breath by breath during the exercise, and the average is calculated for 6-minute segments for subsequent analysis.
|
Change after 2 weeks of crossover.
|
|
Carbon dioxide production
Tijdsspanne: Change after 2 weeks of crossover.
|
Carbon dioxide production is measured using an Ergostik analyser (Geratherm Respiratory, Bad Kissinger, Germany) breath by breath during the exercise, and the average is calculated for 6-minute segments for subsequent analysis.
|
Change after 2 weeks of crossover.
|
|
Minute ventilation
Tijdsspanne: Change after 2 weeks of crossover.
|
Minute ventilation is measured using an Ergostik analyser (Geratherm Respiratory, Bad Kissinger, Germany) breath by breath during the exercise, and the average is calculated for 6-minute segments for subsequent analysis.
|
Change after 2 weeks of crossover.
|
|
Breathing frequency
Tijdsspanne: Change after 2 weeks of crossover.
|
Breathing frequency is measured using an Ergostik analyser (Geratherm Respiratory, Bad Kissinger, Germany) breath by breath during the exercise, and the average is calculated for 6-minute segments for subsequent analysis.
|
Change after 2 weeks of crossover.
|
|
Heart rate
Tijdsspanne: Change after 2 weeks of crossover.
|
Heart rate is continuously recorded during the exercise using a Polar H10 chest strap (Polar, Kempele, Finland), and the average is calculated for 6-minute segments for subsequent analysis.
|
Change after 2 weeks of crossover.
|
|
Blood lactate concentration
Tijdsspanne: Change after 2 weeks of crossover.
|
Capillary blood lactate concentration is assessed at baseline (resting condition) and during the final minute of each exercise step using a Lactate Scout device (EKF Diagnostics, Barleben, Germany).
|
Change after 2 weeks of crossover.
|
|
Rating of perceived exertion
Tijdsspanne: Change after 2 weeks of crossover.
|
Participants are asked to subjectively rate their perceived exertion at specified time points - at rest and subsequently in the last minute of each exercise step.
The Borg's scale 6-20 is used, where 6 means "no exertion" and 20 means "maximal exertion".
|
Change after 2 weeks of crossover.
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Blood glucose concentration
Tijdsspanne: Change after 2 weeks of crossover.
|
Capillary blood glucose concentration is assessed at baseline (resting condition) and during the final minute of each exercise step using an Accu-Chek Inform II device (Roche Diagnostics, Manheim, Germany).
|
Change after 2 weeks of crossover.
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Tereza Rysava, Palacky University
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- FTK_2026_14
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
IPD-tijdsbestek voor delen
IPD-toegangscriteria voor delen
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .